
Teens with higher PFAS levels more likely to regain weight after bariatric surgery: Study
The risk of such gains, which can undermine the procedure's success and cause long-term health issues, was higher in patients who had elevated levels of the compounds prior to the surgery, scientists found in the study, published on Thursday in Obesity.
These so-called forever chemicals, or per- and polyfluoroalkyl substances (PFAS), are notorious for their ability to persist in both the human body and the environment.
Linked to numerous cancers and serious health conditions, PFAS are present in certain firefighting foams and a variety of household items, including nonstick pans, cosmetics and waterproof apparel.
Bariatric surgery, a procedure that alters the digestive system, has long been used as a treatment for severe obesity, with the goals of reducing risks of type 2 diabetes and cardiovascular disease, the study authors noted.
Yet with so many individuals regaining the weight over time, the researchers sought out answers as to why those setbacks might occur.
They said they were particularly curious about the role PFAS exposure might play, since the compounds are known to interfere with metabolic processes.
Several studies, they explained, have already documented such effects in adult populations, but the extent to which those impacts apply to teenagers remains unclear.
'With the growing use of weight loss interventions around the world, it's critical for us to understand the association between PFAS and successful weight loss management,' lead author Brittney Baumert, a postdoctoral fellow at the University of Southern California's Keck School of Medicine, said in a statement.
Baumert and her colleagues tracked 186 adolescents from the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study — a national initiative funded by the National Institutes of Health — who underwent bariatric surgery between 2007 and 2012.
Teen-LABS researchers measured blood levels for seven types of PFAS in each patient before surgery, as well as weight, body mass index and waist circumference before the procedure and six months, one year, three years and five years later.
Baumert and her co-authors harnessed the data from Teen-LABS and divided the adolescents into low, medium and high PFAS exposure groups. They then compared the weight gain and waist expansion outcomes among the cohorts and for each kind of PFAS.
Ultimately, the scientists found that patients with higher blood levels of three types of PFAS — PFOS, PFHxS and PFHpS — exhibited greater weight gain and increases in waist circumference in the one to five years following surgery.
Regarding PFOS specifically, adolescents in the low exposure group with starting body weights of 328 pounds or more regained an average of 35.9 pounds by the five-year mark, the researchers observed. Teens of the same starting weight with the highest PFOS levels gained about 46.9 pounds.
For PFHpS, patients in the lowest exposure group regained about 2.7 of their baseline body weight each year, while those in the highest cohort regained an average of 4.3 percent on average, per the study.
The authors expressed hope that their findings could help inform strategies for improving patient care. Since bariatric surgery is invasive and expensive, they stressed the importance of understanding who the procedure could truly benefit.
In the future, Baumert said she is interested in exploring whether PFAS exposure influences any other weight loss interventions, including the function of GLP-1 medications like Ozempic.
She and her team also noted that the study adds to an expanding body of research that could steer policymakers toward stronger regulation of PFAS, particularly in public water supplies.
'PFAS are a modifiable risk, which is why protective policies are so important to reduce exposure and safeguard public health — especially for vulnerable populations,' Baumert added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
11 hours ago
- Bloomberg
Chinese Drugmaker Aiming to Sell Obesity Meds Soars in HK Debut
Guangzhou Innogen Pharmaceutical Group Co., a Chinese biotech firm looking to tap the vast domestic market for obesity drugs, surged as much as 296% in its trading debut in Hong Kong. Shares of Innogen, which focuses on diabetes and metabolic diseases, climbed to HK$74 Friday, compared with its initial public offering price of HK$18.68. The company raised nearly HK$683 million ($87 million) in its IPO.
Yahoo
19 hours ago
- Yahoo
Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal
Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein-coupled receptors (GPCR) targets within the cardiometabolic and obesity space. The collaboration between the two companies will allow Eli Lilly the exclusive rights to develop and commercialise compounds discovered on Superluminal's AI and machine learning (ML)-powered platform. In return, Superluminal is eligible to receive up to $1.3bn, which includes upfront and near-term payments, an equity investment, development and commercial milestones, as well as tiered royalties on net sales. Lilly has been a long-time backer of Superluminal, with the US big pharma company taking part in a $120m Series A round in September 2024. The $1.3bn partnership with Eli Lilly marks a steep growth trajectory for the company that launched in 2023 with $33m in seed funding. For Eli Lilly, the research pact marks a bolstering of its already successful cardiometabolic and obesity portfolio. Known under the brand names Mounjaro and Zepbound, tirzepatide activates two proteins in the GPCR family – glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Eli Lilly's two drugs earned a combined $8.57bn in Q2 2025 alone. Neither Lilly nor Superluminal confirmed whether more GIP or GLP-1 goalposts will be included in their collaboration, stating the platform will be only used to find 'undisclosed GPCR targets'. Superluminal states on their website that: 'Despite their importance, many GPCRs remain unexplored as drug targets, and we often lack detailed structural information.' Eli Lilly's main rival in the GLP-1RA space, Novo Nordisk, signed a GPCR deal of its own earlier this year. The Danish drugmaker outlaid $2.2bn in a deal with US biotech Septerna in May with the aim of finding and developing small-molecule drugs in obesity and diabetes. This is not the first time Lilly has put money behind GPCR projects. In December 2022, the company signed a partnership worth up to $694m with Tokyo-based Sosei for GPCR drug development, also in the diabetes and metabolic disease space. Superluminal CEO Cony D'Cruz said: '[With Eli Lilly], we aim to develop next-generation medicines that address the urgent and growing global burden of cardiometabolic disease. "We are very excited to be embarking on this collaboration just as we begin to advance our internal drug candidate targeting rare genetic forms of obesity and hypothalamic obesity, and we are committed to bringing safe, efficacious, novel treatments to patients affected by these challenging conditions.' Superliminal's pipeline comprises entirely of pre-clinical candidates. The most advanced is an asset that targets the melanocortin 4 receptor (MC4R), a protein that plays a role in regulating appetite and body weight. "Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Fast Company
19 hours ago
- Fast Company
Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases. Lilly currently dominates the obesity treatment market, which is estimated to be worth $150 billion by the next decade, and is trying to strengthen its foothold in the space through the development of next-generation drugs, acquisitions and partnerships. The deal gives Lilly access to Superluminal's proprietary artificial-intelligence-driven platform to rapidly discover potential drug candidates targeting G-protein-coupled receptors (GPCR)—a class of proteins that can influence a range of physiological processes including metabolism, cell growth and immune responses—the drug developer said on Thursday. In a similar move, Danish rival Novo Nordisk struck a $2.2 billion deal with U.S. biotech Septerna in May to develop oral small-molecule medicines targeting GPCRs for obesity and other cardiometabolic diseases. Lilly has been capitalizing on the overwhelming popularity of the GLP-1 class of medicines, which includes its blockbuster drug Zepbound as well as Novo's Wegovy. It is also developing a keenly watched oral GLP-1 drug, orforglipron, which has failed to meet investors' lofty expectations. The drugmaker teamed up with Hong Kong-listed biotech Laekna last year to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle. Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's platform, the drug developer said. As part of the deal, Superluminal is eligible to receive upfront and milestone payments, an equity investment as well as tiered royalties on net sales, the company said. Boston-based startup Superluminal is developing a wholly owned lead candidate targeting a protein called melanocortin 4 receptor to treat certain rare, genetic forms of obesity and is expected to begin human trials next year. The lead candidate is not part of the deal with Lilly. Superluminal is backed by investors including RA Capital Management, Insight Partners and NVentures, NVIDIA's venture capital arm.